1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsSpecialized Programs of Research Excellence (SPOREs) in Lung Cancer is sponsored by National Cancer Institute (NCI). The NCI invites grant applications for Specialized Programs of Research Excellence (SPORE) in Lung Cancer.
Get alerted about grants like this
Save a search for “National Cancer Institute (NCI)” or related topics and get emailed when new opportunities appear.
Search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Specialized Programs of Research Excellence (SPOREs) - NCI Specialized Programs of Research Excellence (SPOREs) Specialized Programs of Research Excellence (SPOREs) translate novel scientific discoveries into clinical testing, including early-phase clinical trials, for the treatment of cancer. The objective for all SPOREs is to reduce cancer incidence and mortality and to improve survival and quality of life for cancer patients.
SPOREs encourage the advice of patient advocates in SPORE activities.
Current priorities include translational research in: Examples: sarcomas (osteo and soft tissue), brain tumors, heme malignancies, Wilms tumor, etc. Molecular subtypes of common cancers that are uncommon and that have poor outcomes Examples: mantle cell lymphoma, uterine serous cancer, rare subtypes of TNBC, etc. Neuroendocrine cancers of any organ site or that arise through trans-differentiation/lineage plasticity Cancer research with a unique focus on population groups experiencing differences in cancer outcomes.
SPOREs by State or Institution Upcoming SPORE Investigator Meetings GI SPORE Investigators’ Meeting Staff contact: Steven F. Nothwehr, Ph. D.
PDAC Stromal Reprograming Consortium Meeting Staff contact: Peter Ujhazy, M. D. , Ph.
D. Small Cell Lung Cancer Consortium Meeting Staff contact: Peter Ujhazy, M. D.
, Ph. D. Skin and Melanoma SPORE Investigators Meeting Staff contact: Igor Kuzmin, Ph.
D. Breast Cancer SPORE Investigators Meeting Staff contact: Naveena Janakiram, Ph. D.
Gynecological Cancers SPORE Investigator Meeting Staff contact: Naveena Janakiram, Ph. D. NCI SCLC Consortium Meeting Staff contact: Peter Ujhazy, M.
D. , Ph. D.
Lung Cancer SPORE Meeting Staff contact: Peter Ujhazy, M. D. , Ph.
D. Gynecological Cancers SPORE Investigator Meeting Staff contact: Naveena Janakiram, Ph. D.
Based on current listing details, eligibility includes: Institutions that can conduct high-quality balanced translational research approaches on the prevention, etiology, screening, diagnosis, and treatment of lung cancer, with a substantive lung cancer patient population. Applicants should confirm final requirements in the official notice before submission.
Current published award information indicates NCI funds eight lung cancer SPOREs; FY24 funding for Lung SPOREs was $5,553,587. Always verify allowable costs, matching requirements, and funding caps directly in the sponsor documentation.
The current target date is rolling deadlines or periodic funding windows. Build your timeline backwards from this date to cover registrations, approvals, attachments, and final submission checks.
Federal grant success rates typically range from 10-30%, varying by agency and program. Build a strong proposal with clear objectives, measurable outcomes, and a well-justified budget to improve your chances.
Requirements vary by sponsor, but typically include a project narrative, budget justification, organizational capability statement, and key personnel CVs. Check the official notice for the complete list of required attachments.
Yes — AI tools like Granted can help research funders, draft proposal sections, and check compliance. However, always review and customize AI-generated content to reflect your organization's unique strengths and the specific requirements of the solicitation.
Review timelines vary by funder. Federal agencies typically take 3-6 months from submission to award notification. Foundation grants may be faster, often 1-3 months. Check the program's timeline in the official solicitation for specific dates.
Many federal programs offer multi-year funding or allow competitive renewals. Check the official solicitation for continuation and renewal policies. Non-competing continuation applications are common for multi-year awards.
Past winners and funding trends for this program
NCI Continuing Umbrella of Research Experiences (CURE) Academic Career Excellence (ACE) Award (K32) is a grant from the National Cancer Institute (NCI) that funds early postdoctoral fellows from diverse backgrounds, including underrepresented groups, to pursue research training in cancer-related fields. The K32 award supports fellows within 12 months prior to transitioning into, or within the first two years of, a postdoctoral position. The program, operated through NCI's Center to Reduce Cancer Health Disparities (CRCHD), aims to enhance the pool of qualified diverse cancer researchers. Beginning with the June 12, 2025 due date, the CURE ACE Award is available in both Independent Clinical Trial Required and Independent Clinical Trial Not Allowed versions. Eligible applicants must be U.S. citizens or permanent residents at time of award.
NIH NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00) is a grant from the National Institutes of Health (NIH) / National Cancer Institute (NCI) that funds early-stage postdoctoral researchers in cancer-related fields to transition to independent research careers. The award provides a mentored phase (K99) followed by an independent phase (R00), supporting investigators who do not require an extended period of supervised training beyond their doctoral degrees. Eligible applicants must hold a research or clinical doctoral degree and be postdoctoral fellows who have not yet established independent research careers. The March 11, 2026 due date applies; award amounts vary by project.
This Funding Opportunity Announcement (FOA) invites Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) for funding to perform research leading to the development of innovative technologies that may advance progress for early detection and assessment of individuals at risk and for early diagnosis, prognosis and follow-up of type 1 diabetes (T1D). Funding Opportunity Number: RFA-DK-15-024. Assistance Listing: 93.847. Funding Instrument: G. Category: FN,HL. Award Amount: $2M total program funding.
This initiative will stimulate and support innovative research by small business concerns that may lead to the development of novel technologies for the early diagnosis, monitoring and treatment of micro and macro vascular complications of diabetes which are associated with significant morbidity and mortality of the disease and high costs to the health care system. Funding Opportunity Number: PA-14-058. Assistance Listing: 93.847. Funding Instrument: G. Category: FN,HL.